



# Corporate Presentation

June 2022



# Forward-Looking Statements

In addition to historical information, the statements set forth in this presentation include forward-looking statements including, without limitation, statements concerning the Company's expected future financial performance (including the Company's financial outlook for 2022) and expectations for profitability, revenue (including expectations for future milestones, product sales and royalties), operating income, and earnings-per-share, and the Company's plans to repurchase shares under its share repurchase program and to potentially expand the Company's platform through acquisitions. Forward-looking statements regarding the Company's ENHANZE® drug delivery technology may include the possible benefits and attributes of ENHANZE® including its potential application to aid in the dispersion and absorption of other injected therapeutic drugs and facilitating more rapid delivery and administration of larger volumes of injectable medications through subcutaneous delivery, and potentially lowering the treatment burden for patients. Forward-looking statements regarding the Company's ENHANZE® business may include potential growth driven by our partners' development and commercialization efforts (including anticipated new clinical trial starts and ENHANZE® product approvals and launches), projections for future sales revenue of our collaborators' products, potential new ENHANZE® collaborations, collaborative targets and indications for ENHANZE® products, co-formulation intellectual property and the Company's plans to develop new formulations of its API for longer intellectual property protection. Forward-looking statements regarding the Antares acquisition may include the potential acceleration of the Company's growth prospects and revenue durability as a result of the acquisition and the potential for new applications for Antares products. These forward-looking statements are typically, but not always, identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning and involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Actual results could differ materially from the expectations contained in these forward-looking statements as a result of several factors, including unexpected levels of revenues (including royalty, product sales and milestone revenue received from our collaboration partners), expenditures and costs, unexpected delays in the execution of the Company's share repurchase program or planned platform expansion, unexpected results or delays in the growth of the Company's ENHANZE® business (including as a result of unexpected conversion rates), obtaining new co-formulation intellectual property, benefits resulting from the Antares acquisition, or in the development, regulatory review or commercialization of new formulations of the Company's API or its partners' ENHANZE® products, including any potential delays caused by the current COVID-19 global pandemic, regulatory approval requirements, unexpected adverse events or patient outcomes and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the Company's most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission.

## Non-GAAP Financial Measures:

In addition to disclosing financial measures prepared in accordance with U.S. generally accepted accounting principles (GAAP), these materials contain certain non-GAAP financial measures. The Company reports non-GAAP net income and non-GAAP diluted earnings per share and expectations of those measures in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. Reconciliations between GAAP and non-GAAP financial measures are included in these materials.

Note: This presentation contains product names, trademarks and registered trademarks are property of their respective owners

# Halozyme Company Overview

The ENHANZE Drug Delivery Platform combined with innovative autoinjector device technology provides unique therapeutic solutions for partners, patients and health care providers

## Company Details



- >400 employees in 3 locations:
  - San Diego, CA
  - Ewing, NJ
  - Minnetonka, MN
- NASDAQ; HALO
- \$402M in revenue 2021 (+51% vs. 2020)
- In Q2 2022 Halozyme acquired Antares Pharma



Partner of Choice for Patient  
Convenient SC Drug &  
Biologic Treatment

# Halozyme 2022 Pre Antares Acquisition Financial Guidance Highlights

	2021	2022	
<b>Total Revenue</b>	\$443.3M	\$530M-\$560M	<ul style="list-style-type: none"> <li>• ~20-26% growth</li> <li>• Includes one new deal upfront milestone</li> <li>• API and milestone revenue overall similar to 2021</li> <li>• First time annual revenue &gt;\$500M</li> </ul>
<b>Royalty Revenue</b>	\$203.9M	~\$300M	<ul style="list-style-type: none"> <li>• Project ~50% YoY Growth</li> <li>• Second year of projected increase of ~\$100M</li> </ul>
<b>Operating Income</b>	\$275.9M	\$350M-\$380M	<ul style="list-style-type: none"> <li>• ~27-38% growth</li> <li>• &gt;65% Operating Margin</li> <li>• Includes incremental \$20M Op-Ex Investment to maximize ENHANZE® and extend Royalty Revenue durability</li> </ul>
<b>GAAP Diluted EPS</b>	\$2.74	\$1.90-\$2.05	<ul style="list-style-type: none"> <li>• 2021 GAAP Diluted EPS includes \$154.2M one-time benefit from reversal of tax valuation allowance, representing ~\$1.05 per share</li> <li>• 2022 represents first year of income tax expense projected to be ~\$0.55-0.60 per share</li> </ul>
<b>Non- GAAP Diluted EPS</b>	\$2.00	\$2.05-\$2.20	<ul style="list-style-type: none"> <li>• 2021 Non-GAAP Diluted EPS excludes \$154.2M one-time benefit from reversal of tax valuation allowance</li> <li>• 2022 represents first year of income tax expense projected to be ~\$0.55-0.60 per share</li> </ul>

# Halozyme Strategic and Capital Allocation Priorities



**Invest to Maximize  
ENHANZE® Revenue  
Growth and  
Durability**



**Continue to Return  
Capital  
to Shareholders**



**Identify  
Opportunities for  
External Growth**

Potential M&A expanding  
platform technologies

# Antares Portfolio Offers Diversified Commercial and Platform Royalty Revenues

## PROPRIETARY PRODUCTS

### Commercial

XYOSTED®, TLANDO™, and NOCDURNA®



### Development

ATRS-1901  
ATRS-1902  
ATRS-1903

## ROYALTY BUSINESS

### Commercial

Generic EpiPen®, Generic Forsteo® (Ex-U.S.), Sumatriptan, and Makena



### Development

Teva (Generic Forteo® (U.S.)), Idorsia Pharmaceuticals (selatogrel) and Pfizer (undisclosed)




\$184M

2021 REVENUE (+23% VS 2020)

\$36.6M

CASH FROM OPERATIONS FOR 12 MONTHS ENDING 12/31/21

# Antares Immediately Accelerates Halozyme Growth Prospects and Adds Long-Term Durability of Revenues





**ENHANZE®**

Pre-Acquisition 2022 Royalty Revenue Projected to Grow ~50% to ~\$300M (+\$100M YoY)



2027 projection based on approved pre-acquisition products and assumes global approval and launches of 20 additional products in multiple indications. Includes projections for subcutaneous versions for targets not currently approved or commercially available. Assumes approved and under review co-formulation patents, Innovator revenues based on Bloomberg or Evaluate Ltd analyst-based estimates when available. Conversion rates based on Halozyne internal projections. Royalty revenue projections includes targets selected and not yet disclosed. Projected royalty revenue is not risk-adjusted.

# ENHANZE®


## Patented, Proven Platform Technology Enabling Subcutaneous Delivery of IV Drugs

### IV Drug Delivery




Time-consuming administration

### ENHANZE® Platform



Uses Halozyme fully owned rHuPH20 enzyme

### With Subcutaneous Delivery






Temporarily degrades extracellular matrix enabling increased fluid flow and dispersion of drugs co-formulated with ENHANZE®

**>600,000 Patients Treated With Commercial Products Incorporating ENHANZE®**

Multiple Revenue Streams, Growth Driven by Recurring Royalty Revenues

PROJECTED PERCENT OF PRE-ACQUISITION TOTAL REVENUES

		2021(A)		2025
<div> <b>Royalties</b></div>	<ul style="list-style-type: none"><li>• On average mid-single digit</li><li>• Duration, in general minimum of 10 years from launch</li></ul>	~45%	➤	65%
<div> <b>Milestones</b> Typically ~\$160M per target</div>	<ul style="list-style-type: none"><li>• Upfront</li><li>• Development</li><li>• Commercial</li></ul>	~30%	➤	~20%
<div> <b>Product Sales</b></div>	<ul style="list-style-type: none"><li>• API typically cost plus 20%</li><li>• Hylenex<sup>®</sup> (hyaluronidase human injection) Sales</li></ul>	~20-25%	➤	~15%


# ENHANZE®: Durable Revenue and Strong Future Growth Runway



# Wave 1 and 2 Launches

## Record Royalty Revenue & Growth


### Royalty Revenue




1. Halozyme reported results

# Growth in DARZALEX FASPRO® in the U.S.

Reported DARZALEX FASAPRO® Share of Total US DARZALEX® Sales (US) End March 2022<sup>1</sup>



Reported DARZALEX FASPRO® Share of Total US DARZALEX® Sales (US) in Last Month of Trailing Four Quarters<sup>1</sup>



1. Source: Symphony Health (subscription data presented with permission)

# DARZALEX FASPRO®/DARZALEX® SC

Potential for Royalties to More than Double 2021 to 2025

Waves


1

2

3

4

## Total Daratumumab Sales IV+SC (\$B)<sup>1</sup>



## Continued Strong SC Share Gains



**Annualized share 2021: ~58%<sup>2</sup>**

- 2021 Exit share of 60% (EU) to 76%<sup>3</sup> (US) supports projected continued growth 2022+

<sup>1</sup>Analysts consensus obtained from Evaluate Ltd December 2021

<sup>2</sup> Halozyme estimate based on Janssen reported sales Q1-Q3 2021 and data from Symphony Health

<sup>3</sup> Symphony Health December 2021 subscription data (presented with permission)

# Wave 3 Pipeline

Waves

1

2

3

4

3 Key Products With Parent Product Projected at >\$20B Revenue in 2025<sup>(1)</sup>

Product		Indications in or completed Phase 3 as SC with ENHANZE®
Nivolumab (BMS)	IV APPROVED	<ul style="list-style-type: none"><li>• Clear Cell Renal Cell Carcinoma</li></ul>
Atezolizumab (Roche)	IV APPROVED	<ul style="list-style-type: none"><li>• Non-Small Cell Lung Cancer</li></ul>
Efgartigimod (argenx)	IV APPROVED Myasthenia Gravis	<ul style="list-style-type: none"><li>• <b>Myasthenia Gravis</b> (Completed)</li><li>• Pemphigus vulgaris</li><li>• Immune thrombocytopenia</li><li>• CIDP</li></ul>

Potential to launch 3 new SC with ENHANZE® products 2023-2025<sup>2</sup>

<sup>1</sup> Analysts consensus estimates obtained from Evaluate Ltd. December 2021

<sup>2</sup> Halozyne estimated launch time frames based on historical precedents



# Efgartigimod

## Halozyme First Potential Wave 3 Launch

### Waves

1

2

3

4



**Analysts' consensus revenue projection: ~\$2.5B in 2026, with wide range<sup>(1)</sup>**



**First-in-class anti-FcRn for serious auto-immune conditions**



**March 2022<sup>(2)</sup>: argenx announces ADAPT-SC, Evaluating Efgartigimod SC with ENHANZE Met Primary Endpoint**

Demonstrated non-inferior IgG reduction at day 29 with subcutaneously administered efgartigimod compared to IV administration in generalized Myasthenia Gravis patients

BLA to be submitted to FDA by end of 2022

<sup>1</sup> Analysts consensus obtained from Evaluate Ltd December 2021

<sup>2</sup> Topline Results: ADAPT-SC Bridging Study in gMG. Investor Call March 22, 2022

# First Potential Efgartigimod SC Indication with ENHANZE®

Myasthenia Gravis in 2023

## Halozyme Assessed Drivers of Conversion

	Efgartigimod SC	DARZALEX® SC
Growth brand for company	✓	✓
Competitive situation where differentiation key	✓	✓
Potential for reduced treatment burden	✓	✓
Physician practice dynamics support SC	✓	✓

# 15 Partner Products in Development as of May 2022

Current Program/Product	Indications	Phase 1 New Starts	Phase 1 Ongoing	Phase 2 Trial Starts	Phase 3 Trial Starts	Phase 3 Ongoing
ARGX-117 (argenx)	Multifocal motor neuropathy	<div></div>				
Nivolumab+Relatlimab (BMS)	Solid tumors	<div></div>				
Anti-TIM3 (BMS)	Solid tumors	<div></div>				
CAP256V2LS (CAPRISA)	HIV (vaccine)	<div></div>				
Teprotumumab-trbw (Horizon)	Thyroid Eye Disease	<div></div>				
Undisclosed (Janssen)	Undisclosed	<div></div>				
Rilpivirine (Janssen)	HIV	<div></div>				
Undisclosed (Roche)	Undisclosed	<div></div>				
TAK-881 (Takeda)	Undisclosed	<div></div>				
Cabotegravir (ViiV)	HIV	<div></div>				
N6LS bnAb (ViiV)	HIV (treatment)	<div></div>				
Ocrelizumab (Roche)	Multiple sclerosis	<div></div>				
Nivolumab (BMS)	Solid tumors	<div></div>				
Atezolizumab (Roche)	NSCLC	<div></div>				
Efgartigimod (argenx)	CIDP	<div></div>				
Efgartigimod (argenx)	Immune thrombocytopenia	<div></div>				
Efgartigimod (argenx)	Pemphigus vulgaris	<div></div>				
Efgartigimod (argenx)	MG	<div></div>				

## Recent 2022 Progress:



- 1 new Phase 1 start (N6LS)
- 1 new Phase 3 start (Ocrevus)
- Other starts remain on track

**MET ENDPOINT**

Regulatory Submission by end 2022

**Expected in 2022: At Least 4 New Products to Enter Clinic and 5 New Phase 2/3 Starts**


# Broad Applicability of ENHANZE® Platform = Opportunity



	Monoclonal antibodies Antibody Fragments antibodies		Bi-specific antibodies	Small Molecules
Potential Benefits	IV to SC for Competitive Differentiation Co-formulation IP			Oral to SC for compliance SC/IM to SC Extended dosing
Approved	DARZALEX FASPRO®			
Products in Development (examples)	Efgartigimod Atezolizumab		Janssen (undisclosed)	Cabotegravir

# 2025 Goal

10 Approved SC ENHANZE® Products Generating Royalty Revenues, Multiple Waves to Come



# New Longer IP rHuPH20

Opportunity to Increase and Extend Halozyme Revenue Durability


New rHuPH20, with  
extended room  
temperature stability

For current and new  
partners seeking new  
option for patient self-  
administration with longer  
IP coverage

Patent protected to  
2032 Europe  
2034 US

# ENHANZE®

## A Royalty Growth Story



2027 Projection based on approved products and assumes global approval and launches of 20 additional products in multiple indications. Includes projections for subcutaneous versions for targets not currently approved or commercially available. Assumes approved and under review co-formulation patents, Innovator revenues based on Bloomberg or Evaluate Ltd analyst-based estimates when available. Conversion rates based on Halozyne internal projections. Royalty revenue projections includes targets selected and not yet disclosed. Projected royalty revenue is not risk-adjusted.

# Why the Traditional Patent Cliff Dynamic Does Not Apply to ENHANZE®



**No third-party biosimilar company can target the \$1B potential revenue with just one biosimilar product at patent expiry**



ENHANZE® IP extends to 2024 (EU) and 2027 (US)



>20 products drive Halozyme ~\$1B potential



Project multiple SC products with ENHANZE® protected by co-formulation patents post 2030



High cost and complexity for biosimilar company

# Why the Traditional Patent Cliff Dynamic Does Not Apply to ENHANZE®



API SUPPLY  
STRATEGY

Designed to  
Retain and Expand  
Current and  
New Partners



**Multiple partner products patent protected beyond 2027**



**Established Safety Profile**

ENHANZE® safety track record in >600,000 post-marketing patients



**Reliable Low-Cost ENHANZE® API**

New higher yield, lower cost ENHANZE® API: reduces incentive to switch

# Halozyme Strategic and Capital Allocation Priorities



**Invest to Maximize  
ENHANZE® Revenue  
Growth and  
Durability**



**Continue to Return  
Capital  
to Shareholders**




**Identify  
Opportunities for  
External Growth**

Potential M&A expanding  
platform technologies


# Pipeline and New Deal Progress Drives Significant Revenue

## 3 Year Forward Milestone Revenue Projection



Includes development, commercial and new agreement upfront milestones and other collaboration revenue. Updated through March 2022.

# Capital Return Plan



# Halozyme Strategic and Capital Allocation Priorities

**Invest to Maximize  
ENHANZE®  
Revenue Growth  
and Durability**



**Continue to Return  
Capital to  
Shareholders**



**Identify  
Opportunities for  
External growth**

Potential M&A expanding  
platform technologies



# Halozyme Strategic and Capital Allocation Priorities

## Strategic & Capital Allocation Priorities



Invest to Maximize  
ENHANZE® Revenue Growth  
and Durability



**Identify Opportunities for  
External Growth**  
Potential BD Expanding  
Platform Technologies



Return Capital to  
Shareholders

## Business Development Priorities

Differentiated platform  
technologies with broad  
application and licensing  
opportunities

Accretive to financial profile  
today with clear strategy for  
unlocking substantial upside

Low investment requirement to  
execute on vision of enhancing  
revenue growth and durability

# Leveraging Our Joint Expertise to Unlock High Volume Drug Delivery Opportunity



Commercially validated  
ENHANZE® platform technology,  
world-class partners

Potential to support rapid delivery  
when used with an auto injector

Extensive experience and  
infrastructure necessary to support  
product expansion



Leading auto injector platform  
and domain expertise

Flexible delivery force, injection  
speed and needle length

Broad technology capabilities  
with strong underlying patent  
protection



**Partner of Choice for  
Patient Convenient  
SC Drug and Biologic  
Treatment**

# Differentiated Device Platforms Are Widely Licensable

## QuickShot™ and BigShot™ Auto Injectors



- Accepts up to 1mL and 2.25mL pre-filled syringe
- SC or IM
- Fast injection of highly viscous drug products

## VIBEX™ Auto Injectors



- Accepts 1mL pre-filled syringe
- SC or IM triggering collar shields needle from view and locks in place

## VAI™ Auto Injector



- Compatible with up to 2.25mL pre-filled syringe
- SC or IM
- Easily convertible to different fill volumes / needle lengths

## Pen Injector System



- Multi-dose, disposable pen injector technology
- Able to deliver up to 30 days of drug

PRODUCTS / PARTNERS

**XYOSTED®**  
(testosterone enanthate) injection ©

**amag**  
Makena

**Pfizer**  
Undisclosed

**idorsia**  
Selatogrel

**teva**  
Generic Imitrex

**teva**  
Generic EpiPen

**Otrexup**  
Assertio Holdings

**antares**  
pharma  
ATRS 1902  
(development stage)

**teva**  
Generic Forteo

Flexible Delivery Force, Injection Time, Needle Length Support Broad Application

# Licensable Differentiated Device Platforms Can Drive Meaningful Revenue Opportunities

## Current Applications

Branded devices with off-patent API	 <small>(testosterone enanthate) injection ©</small>	
Branded / unbranded generic devices	 <small>Generic EpiPen</small>	 <small>Generic Imitrex</small>
Branded product and product life cycle management	 <small>Selatogrel</small>	
Subcutaneous / intramuscular viscous therapies	 <small>(testosterone enanthate) injection ©</small>	 <small>Makena</small>

## Potential Future Applications

Multi-billion dollar large and small molecule opportunity with potential to convert to Auto Injector Device

- High and low viscosity
- Today up to 2.25mL

Potential to develop rapid delivery 5mL Auto Injector on already validated QuickShot™ / BigShot™ platform

**Robust opportunity for new product launches through 2030**

Technology Platform with Broad Applicability

# Established U.S. Commercial Footprint Drives Near-Term Revenue Growth with Business Development Opportunity for Future Growth

## Focus

- XYOSTED<sup>®</sup> Launched November 2018
- TLANDO<sup>™</sup> Launched June 2022
- NOCDURNA<sup>®</sup> Launched March 2021

## Sales Force

- 108 representatives
- 12 regional managers
- 2 area directors

## Targeting

- 16,000 urologists, endocrinologists and primary care physicians
- 95% top 3 decile testosterone prescribers covered

## Business development for future growth

- Urology
- Endocrinology

Antares Corporate Presentation March 2022



# Transaction Rationale Summary

Strategic Fit	<ul style="list-style-type: none"><li>• Differentiated auto injector platform that can be licensed widely and potentially extend to higher volume auto injectors</li><li>• Ability to leverage existing U.S. commercial infrastructure to promote proprietary products with substantial growth trajectory</li></ul>
Risk Profile	<ul style="list-style-type: none"><li>• De-risked platform with a suite of approved commercial products (wholly owned and partnered)</li></ul>
Revenue Opportunity	<p>Multiple Opportunities:</p> <ul style="list-style-type: none"><li>• Existing small volume auto injector technology</li><li>• Potential to extend to high volume, up to 5.0mL</li><li>• Commercial products (XYOSTED®, TLANDO™, NOCDURNA®)</li></ul>
Proven Track Record of Commercial Success	<ul style="list-style-type: none"><li>• Meaningful opportunity for increased revenues and expansion into additional, high revenue segments</li></ul>
Financial Fit	<ul style="list-style-type: none"><li>• Expected to be accretive to revenue and non-GAAP EPS in 2022 with multiple drivers to augment growth post 2027</li></ul>



## Financial Results Appendix

# Halozyme 2022 Pre Antares Acquisition Financial Guidance Highlights

	2021	2022	
<b>Total Revenue</b>	\$443.3M	\$530M-\$560M	<ul style="list-style-type: none"> <li>• ~20-26% growth</li> <li>• Includes one new deal upfront milestone</li> <li>• API and milestone revenue overall similar to 2021</li> <li>• First time annual revenue &gt;\$500M</li> </ul>
<b>Royalty Revenue</b>	\$203.9M	~\$300M	<ul style="list-style-type: none"> <li>• Project ~50% YoY Growth</li> <li>• Second year of projected increase of ~\$100M</li> </ul>
<b>Operating Income</b>	\$275.9M	\$350M-\$380M	<ul style="list-style-type: none"> <li>• ~27-38% growth</li> <li>• &gt;65% Operating Margin</li> <li>• Includes incremental \$20M Op-Ex Investment to maximize ENHANZE® and extend Royalty Revenue durability</li> </ul>
<b>GAAP Diluted EPS</b>	\$2.74	\$1.90-\$2.05	<ul style="list-style-type: none"> <li>• 2021 GAAP Diluted EPS includes \$154.2M one-time benefit from reversal of tax valuation allowance, representing ~\$1.05 per share</li> <li>• 2022 represents first year of income tax expense projected to be ~\$0.55-0.60 per share</li> </ul>
<b>Non- GAAP Diluted EPS</b>	\$2.00	\$2.05-\$2.20	<ul style="list-style-type: none"> <li>• 2021 Non-GAAP Diluted EPS excludes \$154.2M one-time benefit from reversal of tax valuation allowance</li> <li>• 2022 represents first year of income tax expense projected to be ~\$0.55-0.60 per share</li> </ul>

Post-Acquisition Guidance will be provided August 2022

# GAAP to Non-GAAP Reconciliation: Net Income and Diluted EPS 2022 Guidance

\$ U.S. in Millions, except EPS (unaudited)

	2022	2021
<b>GAAP Net Income</b>	<b>\$ 270 - 295</b>	<b>\$ 402.7</b>
Adjustments:		
Inducement expense related to convertible notes .....	—	21.0
Share-based compensation .....	22 - 25	20.8
Amortization of debt discount .....	4 - 4	3.9
Income tax benefit .....	—	(154.2)
Income tax effect of above adjustments .....	(6) - (7)	(0.1)
<b>Non-GAAP Net Income</b>	<b>\$ 290 - 315</b>	<b>\$ 294.1</b>
<b>GAAP Diluted EPS</b>	<b>\$ 1.90 - 2.05</b>	<b>\$ 2.74</b>
Adjustments:		
Inducement expense related to convertible notes .....	—	0.14
Share-based compensation .....	0.16 - 0.17	0.14
Amortization of debt discount .....	0.04 - 0.04	0.03
Income tax benefit .....	—	(1.05)
Income tax effect of above adjustments .....	(0.04) - (0.05)	—
<b>Non-GAAP Diluted EPS</b>	<b>\$ 2.05 - 2.20</b>	<b>\$ 2.00</b>
<b>GAAP &amp; Non-GAAP Diluted Shares</b>	<b>142 - 143</b>	<b>146.8</b>

Dollar amounts, as presented, are rounded. Consequently, totals may not add up.